Cargando…

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tirnea, Livius, Bratosin, Felix, Vidican, Iulia, Cerbu, Bianca, Turaiche, Mirela, Timircan, Madalina, Margan, Madalin-Marius, Marincu, Iosif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/
https://www.ncbi.nlm.nih.gov/pubmed/33799535
http://dx.doi.org/10.3390/medicina57030257
_version_ 1783670478457536512
author Tirnea, Livius
Bratosin, Felix
Vidican, Iulia
Cerbu, Bianca
Turaiche, Mirela
Timircan, Madalina
Margan, Madalin-Marius
Marincu, Iosif
author_facet Tirnea, Livius
Bratosin, Felix
Vidican, Iulia
Cerbu, Bianca
Turaiche, Mirela
Timircan, Madalina
Margan, Madalin-Marius
Marincu, Iosif
author_sort Tirnea, Livius
collection PubMed
description Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients.
format Online
Article
Text
id pubmed-7998120
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79981202021-03-28 The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients Tirnea, Livius Bratosin, Felix Vidican, Iulia Cerbu, Bianca Turaiche, Mirela Timircan, Madalina Margan, Madalin-Marius Marincu, Iosif Medicina (Kaunas) Article Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients. MDPI 2021-03-11 /pmc/articles/PMC7998120/ /pubmed/33799535 http://dx.doi.org/10.3390/medicina57030257 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Tirnea, Livius
Bratosin, Felix
Vidican, Iulia
Cerbu, Bianca
Turaiche, Mirela
Timircan, Madalina
Margan, Madalin-Marius
Marincu, Iosif
The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title_full The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title_fullStr The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title_full_unstemmed The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title_short The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
title_sort efficacy of convalescent plasma use in critically ill covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/
https://www.ncbi.nlm.nih.gov/pubmed/33799535
http://dx.doi.org/10.3390/medicina57030257
work_keys_str_mv AT tirnealivius theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT bratosinfelix theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT vidicaniulia theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT cerbubianca theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT turaichemirela theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT timircanmadalina theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT marganmadalinmarius theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT marincuiosif theefficacyofconvalescentplasmauseincriticallyillcovid19patients
AT tirnealivius efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT bratosinfelix efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT vidicaniulia efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT cerbubianca efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT turaichemirela efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT timircanmadalina efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT marganmadalinmarius efficacyofconvalescentplasmauseincriticallyillcovid19patients
AT marincuiosif efficacyofconvalescentplasmauseincriticallyillcovid19patients